Marc Stapley - Veracyte CEO Director
| VCYT Stock | USD 34.76 0.92 2.72% |
Insider
Marc Stapley is CEO Director of Veracyte
| Age | 55 |
| Phone | 650 243 6300 |
| Web | https://www.veracyte.com |
Marc Stapley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marc Stapley against Veracyte stock is an integral part of due diligence when investing in Veracyte. Marc Stapley insider activity provides valuable insight into whether Veracyte is net buyers or sellers over its current business cycle. Note, Veracyte insiders must abide by specific rules, including filing SEC forms every time they buy or sell Veracyte'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marc Stapley over two months ago Disposition of 5748 shares by Marc Stapley of Veracyte at 44.12 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Disposition of 6250 shares by Marc Stapley of Glaukos Corp at 32.0 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Disposition of 5971 shares by Marc Stapley of Veracyte at 21.1 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Disposition of 13286 shares by Marc Stapley of Veracyte at 24.0 subject to Rule 16b-3 |
Veracyte Management Efficiency
The company has return on total asset (ROA) of 0.0132 % which means that it generated a profit of $0.0132 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0218 %, meaning that it created $0.0218 on every $100 dollars invested by stockholders. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sven MD | Merus BV | 62 | |
| Matthew MD | Ideaya Biosciences | N/A | |
| Jessie MBA | Rocket Pharmaceuticals | N/A | |
| Cecilia Geuijen | Merus BV | N/A | |
| Tanya MS | Replimune Group | 53 | |
| Eric Olson | Viridian Therapeutics | N/A | |
| Ronald Evans | Syndax Pharmaceuticals | 76 | |
| MBA MBA | Rocket Pharmaceuticals | 43 | |
| Paul Herzich | Solid Biosciences LLC | 47 | |
| JD Howton | Solid Biosciences LLC | 53 | |
| Dennis Mulroy | AnaptysBio | 70 | |
| Matthew Kapusta | Uniqure NV | 52 | |
| Jeff Knight | Crinetics Pharmaceuticals | 54 | |
| Scott Rottinghaus | Enanta Pharmaceuticals | N/A | |
| Erin Brennan | Solid Biosciences LLC | 51 | |
| James Hassard | Crinetics Pharmaceuticals | 58 | |
| Martin JD | Rocket Pharmaceuticals | 49 | |
| Esq JD | Ideaya Biosciences | 52 | |
| Marc MD | Kura Oncology | 50 | |
| Kari JD | Cytokinetics | N/A | |
| Cornelis Kruif | Merus BV | 60 | |
Management Performance
| Return On Equity | 0.0218 | ||||
| Return On Asset | 0.0132 |
Veracyte Leadership Team
Elected by the shareholders, the Veracyte's board of directors comprises two types of representatives: Veracyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veracyte. The board's role is to monitor Veracyte's management team and ensure that shareholders' interests are well served. Veracyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veracyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Brainin, Executive Officer | ||
| John Leite, Chief Business | ||
| Annie McGuire, Sr Counsel | ||
| Tracy Morris, VP Communications | ||
| Corinne Danan, Senior President | ||
| Tina Nova, Director | ||
| Bonnie Anderson, Co-Founder, CEO and President Director and Member of Non-Management Equity Award Committee | ||
| Keith Gligorich, Senior Operations | ||
| Rebecca Chambers, Executive CFO | ||
| Jonathan Wygant, VP Officer | ||
| Phillip MD, Chief Officer | ||
| Beverly CPA, VP Controller | ||
| Karen Possemato, Communications Marketing | ||
| Giulia Kennedy, Chief Scientific Officer, Chief Medical Officer | ||
| Steven French, Senior Officer | ||
| Marc Stapley, CEO Director |
Veracyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veracyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0218 | ||||
| Return On Asset | 0.0132 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.38 B | ||||
| Shares Outstanding | 77.5 M | ||||
| Shares Owned By Insiders | 0.80 % | ||||
| Shares Owned By Institutions | 99.20 % | ||||
| Number Of Shares Shorted | 3.13 M | ||||
| Price To Earning | (10.61) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.